Intratumoral Cancer Therapies Market

DelveInsight’s Intratumoral Cancer Therapies Market Insights report includes a comprehensive understanding of current treatment practices, Intratumoral Cancer Therapies emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), Japan].

Some facts of the Intratumoral Cancer Therapies market report are:

• In 2021, the total Intratumoral Cancer Therapies market size was approximately USD 93 million which is expected to rise during the study period (2019–2032).
• In 2021, the total Intratumoral Cancer Therapies target patient pool cases across 7MM were about 469 K which are expected to grow during the study period, i.e., 2019–2032.
• Currently, only three intratumoral therapies are approved, namely, IMLYGIC (Talimogene laherparepvec/T-VEC; Amgen) approved in the US, Europe and Japan in 2015, DELYTACT (teserpaturev/G47∆; Daiichi Sankyo) approved in Japan in 2021 and HENSIFY (Nanobiotix) approved in European market in 2019.
• Some of the companies working in the Intratumoral Cancer Therapies market are Daiichi Sankyo, Amgen, Idera Pharmaceuticals, Philogen, Oncolys BioPharma, Highlight Therapeutics, Momotaro-Gene, Ziopharm, Takara Bio, NanOlogy, SillaJen, Hookipa Biotech GmbH, Lokon Pharma AB, Checkmate Pharmaceuticals, Istari Oncology, Vyriad, Merck Sharp & Dohme Corp., OncoSec Medical Incorporated, AiViva Biopharma, Immunicum AB, Exicure, Immunovative Therapies, Provectus Biopharmaceuticals, Sirnaomics, Apexigen, Replimune, Merck & Co (Viralytics), Moderna Therapeutics, Intensity Therapeutics, DNAtrix, Treovir, Nanobiotix and others.

Download the report to understand which factors are driving Intratumoral Cancer Therapies Market @Intratumoral Cancer Therapies Market

Intratumoral Cancer Therapies Overview

Intratumoral Cancer therapy refers to any therapy that is delivered in very close anatomical proximity to a tumor with the intention of direct uptake by tumors or tumor cells. It is a therapeutic strategy which aims to use the tumor as its own vaccine.

Intratumoral Cancer Therapies Epidemiology Segmentation

According to DelveInsight estimates, there were approximately 469K Intratumoral Cancer Therapies targeted patient pool in the 7MM in 2021.

Among the 7MM countries, the US had the highest incidence of Intratumoral Cancer Therapies in 2021.

The Intratumoral Cancer Therapies market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Incident cases of selected cancer types
• Target Patient Pool of Intratumoral Cancer Therapy by Cancer Types
• Total Treated cases by the line of therapies

Download the report to understand which factors are driving Intratumoral Cancer Therapies epidemiology trends @Intratumoral Cancer Therapies Epidemiological Insights.

Intratumoral Cancer Therapies Pipeline Therapies and Key Companies

Some of the Intratumoral Cancer companies working in the market are Daiichi Sankyo, Amgen, Idera Pharmaceuticals, Philogen, Oncolys BioPharma, Highlight Therapeutics, Momotaro-Gene, Ziopharm, Takara Bio, NanOlogy, SillaJen, Hookipa Biotech GmbH, Lokon Pharma AB, Checkmate Pharmaceuticals, Istari Oncology, Vyriad, Merck Sharp & Dohme Corp., OncoSec Medical Incorporated, AiViva Biopharma, Immunicum AB, Exicure, Immunovative Therapies, Provectus Biopharmaceuticals, Sirnaomics, Apexigen, Replimune, Merck & Co (Viralytics), Moderna Therapeutics, Intensity Therapeutics, DNAtrix, Treovir, Nanobiotix and others

Learn more about the Intratumoral Cancer Therapies therapies in clinical trials @ Drugs for Intratumoral Cancer Therapies Treatment

Scope of the Intratumoral Cancer Therapies Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Intratumoral Cancer Therapies Companies: Daiichi Sankyo, Amgen, Idera Pharmaceuticals, Philogen, Oncolys BioPharma, Highlight Therapeutics, Momotaro-Gene, Ziopharm, Takara Bio, NanOlogy, SillaJen, Hookipa Biotech GmbH, Lokon Pharma AB, Checkmate Pharmaceuticals, Istari Oncology, Vyriad, Merck Sharp & Dohme Corp., OncoSec Medical Incorporated, AiViva Biopharma, Immunicum AB, Exicure, Immunovative Therapies, Provectus Biopharmaceuticals, Sirnaomics, Apexigen, Replimune, Merck & Co (Viralytics), Moderna Therapeutics, Intensity Therapeutics, DNAtrix, Treovir, Nanobiotix and others
• Therapeutic Assessment: Intratumoral Cancer Therapies current marketed and emerging therapies
• Unmet Needs, KOL’s views, Analyst’s views, Intratumoral Cancer Therapies Market Access and Reimbursement
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

Discover more about emerging Intratumoral Cancer Therapies in development @Intratumoral Cancer Therapies Clinical Trials

Table of Contents

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/intratumoral-cancer-therapies-market